GlaxoSmithKline Consumer Healthcare Ltd. (erstwhile SmithKline Beecham Consumer Healthcare) has posted a much better performance in September quarter, as compared to the June quarter. The malted beverage major reported a 4% growth in topline and finished the quarter with 15% dip in bottomline.
Operating Profit (EBDIT)
Operating Profit Margin (%)
Profit before Tax
Profit after Tax/(Loss)
Net profit margin (%)
No. of Shares (eoy) (m)
Diluted Earnings per share*
Current P/e ratio
The company had posted shocking results in June quarter. SBCH posted a never before 26% decline in the topline in 2QFY03. This resulted in the margins getting squeezed and the company finally finished the quarter with a significant 45% dip in bottomline. The company attributed this dip to an inventory correction as well as delay in commissioning of its new plant in Sonepat, which effectively meant a delay in improvement of efficiencies.
The company managed to just about stop an operating margin slide, but higher depreciation (Rs 59.4 m) on account of the new Sonepat plant (got commisioned in July 2002), slide in other income, as well as extraordinary expenses towards VRS (Rs 41.4 m) and restructuring, saw profits decline by 15% during 3QFY03. The company has closed its packing operations in Kolkata with affect from August 31, 2002.
Patent and trademark
Def. Rev. exps.
Please note for the comparision on a YoY basis, we have taken numbers that had been stated by the management last year. The company seems to have restated some numbers, as a result of which the bottomline dip during September quarter is coming to 12.3% (as opposed to 15% shown in the table). We haven't received the company's press release and consequently, are showing the comparision based on the numbers made available last year.
The poor results in June quarter had shaken investor confidence towards the counter. GlaxoSmithKline Consumer anyway never got higher valuations owing to its one product category focus. The parent's other 100% subsidiary was always a cause for concern. But the blip in quarterly results saw the stock price lose a significant market cap.
The stock is trading at Rs 282, a P/E of 12.7x annualised 9mFY03 earnings. Though the performance has brought some relief to investors, a full fledged recovery in the company's fortunes seems still some time away. The company's statement: "Due to the recessionary trends still prevailing in the malted food industry the capacity utilisation of the plant (Sonepat) has been below the forecast level", gives an indication of the difficult market conditions for SBCH. Having said that, GlaxoSmithKline Consumer has traditionally had a stable business growth and on the longer term we remain positive on the company's progress.
GSK Consumer Healthcare declared results for the quarter ended September 2016. The revenues dropped by 1.3% during the quarter as compared to a year ago; while the profits declined by 16.6% YoY during the quarter.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India. Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: email@example.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407